Price$12.17+0.66 (+5.73%)
01:30 PM07:45 PM
News · 26 weeks44-71%
2025-11-022026-04-26
Mix2590d
- Insider11(44%)
- SEC Filings6(24%)
- Other5(20%)
- Earnings2(8%)
- Analyst1(4%)
Latest news
25 items- SECSEC Form DEFA14A filed by Fortrea Holdings Inc.DEFA14A - Fortrea Holdings Inc. (0001965040) (Filer)
- SECSEC Form DEF 14A filed by Fortrea Holdings Inc.DEF 14A - Fortrea Holdings Inc. (0001965040) (Filer)
- PRFortrea Announces Date for First Quarter 2026 Financial Results and Conference CallDURHAM, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its first quarter 2026 financial results before the market opens on Tuesday, May 5, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results. To participate in the conference call, participants should pre-register via the call registration link. All registrants will receive dial-in details and a unique PIN providing access to the live call. To avoid potential delays, participants are encouraged to join at least 10 minutes prior to the start of the call. The live webcast c
- PRFortrea Unveils Fortrea Intelligent Technology™ to Help Sponsors and Sites Run Smarter, More Integrated TrialsHighlights: Designed to transform clinical trial operations for sponsors, sites and study teamsPersona driven, AI-powered solutions automate workflows and streamline oversight to help improve trial speed, predictability and qualityBuilds on Fortrea's flagship platform Xcellerate® to deliver near-real-time, role-based insights DURHAM, N.C., April 07, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global clinical research organization (CRO), today unveiled Fortrea Intelligent Technology™(FIT), a suite of innovative technology solutions designed to transform clinical trial operations. By integrating persona-driven, AI-powered solutions that automate workflows, streamline oversig
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Fortrea Holdings Inc.SCHEDULE 13G/A - Fortrea Holdings Inc. (0001965040) (Subject)
- INSIDERSEC Form 4 filed by Russell Erin L4 - Fortrea Holdings Inc. (0001965040) (Issuer)
- INSIDERChief Operating Officer Morais Mark A. sold $16,633 worth of shares (1,804 units at $9.22) and converted options into 4,284 shares, increasing direct ownership by 4% to 69,899 units (SEC Form 4)4 - Fortrea Holdings Inc. (0001965040) (Issuer)
- INSIDERChief Financial Officer Mcconnell Jill G. converted options into 4,284 shares and sold $16,633 worth of shares (1,804 units at $9.22), increasing direct ownership by 4% to 72,276 units (SEC Form 4)4 - Fortrea Holdings Inc. (0001965040) (Issuer)
- INSIDERSEC Form 4 filed by Fortrea Holdings Inc.4 - Fortrea Holdings Inc. (0001965040) (Issuer)
- INSIDERSEC Form 4 filed by Fortrea Holdings Inc.4 - Fortrea Holdings Inc. (0001965040) (Issuer)
- INSIDERSEC Form 4 filed by Fortrea Holdings Inc.4 - Fortrea Holdings Inc. (0001965040) (Issuer)
- INSIDERSEC Form 4 filed by Chief Accounting Officer Parks Robert4 - Fortrea Holdings Inc. (0001965040) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Morais Mark A.4 - Fortrea Holdings Inc. (0001965040) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Mcconnell Jill G.4 - Fortrea Holdings Inc. (0001965040) (Issuer)
- PRFortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)DURHAM, N.C., March 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization, today announced the granting of an inducement award of restricted stock units ("RSUs") on March 10, 2026, to four newly hired employees. The award consisted of 130,000 RSUs that vest in three equal annual installments starting March 10, 2027, subject to the employee's continuous employment through the applicable vesting date. The RSUs are subject to the terms and conditions of the Company's Amended and Restated 2025 Inducement Award Plan and the award agreements covering the grants. These awards follow Nasdaq Listing Rule 5635(c)(4) and are intended as an
- SECSEC Form 144 filed by Fortrea Holdings Inc.144 - Fortrea Holdings Inc. (0001965040) (Subject)
- SECSEC Form 144 filed by Fortrea Holdings Inc.144 - Fortrea Holdings Inc. (0001965040) (Subject)
- ANALYSTFortrea upgraded by TD Cowen with a new price targetTD Cowen upgraded Fortrea from Hold to Buy and set a new price target of $15.00
- SECSEC Form 10-K filed by Fortrea Holdings Inc.10-K - Fortrea Holdings Inc. (0001965040) (Filer)
- SECFortrea Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Fortrea Holdings Inc. (0001965040) (Filer)
- PRFortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 GuidanceRevenue and Adjusted EBITDA results delivered in line with stated full-year targetsFull‑year cost savings exceeded previously communicated targets Highlights: Revenues of $660.5 million for the fourth quarter and $2,723.4 million for the full yearFourth-quarter book-to-bill ratio of 1.14x, resulting in 1.02x book-to-bill for the trailing 12 monthsGAAP net loss of $(32.5) million, or $(0.35) per diluted share for the fourth quarter; $(986.2) million, or $(10.81) per diluted share for the full yearAdjusted EBITDA of $54.0 million for the fourth quarter and $189.9 million for the full yearAdjusted net income of $9.2 million, or $0.09 per diluted share for the fourth quarter; $40.4 million, or
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Fortrea Holdings Inc.SCHEDULE 13G/A - Fortrea Holdings Inc. (0001965040) (Subject)
- PRFortrea Expands Executive Team, Appointing Oren Cohen as Chief Medical Officer and Scott Dove as President of Clinical Pharmacology ServicesDURHAM, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced it has expanded its executive team. Oren Cohen, MD who previously served as both Fortrea's chief medical officer (CMO) and president of Clinical Pharmacology Services (CPS) is now dedicated to his CMO responsibilities, namely medical strategy, scientific leadership, ethics and governance oversight across Fortrea's portfolio. Scott Dove, PhD joins Fortrea as its new president of CPS, responsible for Fortrea's early clinical development solutions across its global network of clinical research units. Cohen and Dove both serve on Fortrea'
- INSIDERChief Operating Officer Morais Mark A. converted options into 2,255 shares and sold $16,365 worth of shares (1,179 units at $13.88), increasing direct ownership by 2% to 58,052 units (SEC Form 4)4 - Fortrea Holdings Inc. (0001965040) (Issuer)
- INSIDERChief Financial Officer Mcconnell Jill G. sold $12,229 worth of shares (881 units at $13.88) and converted options into 1,685 shares, increasing direct ownership by 1% to 59,574 units (SEC Form 4)4 - Fortrea Holdings Inc. (0001965040) (Issuer)
FTRE FAQ
5 questionsWhere does FTRE stock trade?
Fortrea Holdings Inc. (FTRE) is listed on NASDAQ.What sector and industry is FTRE in?
Fortrea Holdings Inc. operates in the Health Care sector, Medical Specialities industry.What are analysts saying about FTRE?
Fortrea Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from TD Cowen: Buy with a $1500.00 price target on 2026-03-09. Recent price targets range from $600.00 to $2500.00.What companies are similar to FTRE?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), NTRA (Natera Inc.). Compare FTRE side-by-side with any of them on Quantisnow.How can I track FTRE on Quantisnow?
Quantisnow aggregates Fortrea Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FTRE to receive live email and push alerts on every new disclosure.